Episode 18 – Scaling up organoids
Posted: 28 March 2023 | Drug Target Review | No comments yet
Tune into this podcast to hear experts discussing scaling up 3D organoids!
The final episode of our Organoids Miniseries is now live! In this episode, sponsored by Molecular Devices, we discuss the processes involved in scaling up three-dimensional (3D) organoids.
This conversation features Dr Vicky Marsh Durban, Chief Executive Officer at Cellesce Limited, and Dr Magdalena Kasendra, who is the Director of Research and Development at Centre for Stem Cell and Organoid Medicine.
Key learning points:
- Process of scaling up 3D high-throughput cell cultures
- Induced pluripotent stem cells (iPSCs) versus adult stem cells
- Discover different kinds of solutions to overcome challenges related to scaling up 3D organoids.
Dr Victoria Marsh Durban
Victoria was appointed CEO of Cellesce in January 2022, and has led the company through its’ recent acquisition by Molecular Devices, which completed at the end of 2022. Having originally joined Cellesce as Lead Scientist in 2019, she also held the role of Chief Operating Officer and was appointed to the Board of Directors in January 2021. Prior to Cellesce, Vicky held the role of Head of Cell Biology at ReNeuron.
Vicky completed her PhD.at Cardiff University in 2008 in the field of cancer genetics with a focus on models of gastrointestinal tract cancers. She subsequently moved to the University of California, San Francisco (UCSF) where she held a post-doctoral research scholarship investigating targeted therapeutic approaches in malignant melanoma. In 2014 she returned to Cardiff to take up a Research Fellowship at the European Cancer Stem Cell Research Institute.
Dr Magdalena Kasendra
Magdalena Kasendra is the Director of Research and Development at the Centre for Stem Cell and Organoid Medicine (CuSTOM). She leads a multifaceted effort to translate breakthrough discoveries in stem cell biology and organ development into innovative organoid-based solutions to address unmet medical needs. These include organoid-based platforms enabling discovery and development of safer and more efficient drugs, precision medicine applications and organoid-based tissue replacement therapies.
Prior to joining CuSTOM’s leadership team, she managed the multidisciplinary team responsible for developing, translating and commercialising Organs-on-Chips technology at Emulate Inc, a spin-off from Harvard’s Wyss Institute for Biologically Inspired Engineering. This research has led to major advances in bioengineering of intestinal tissue by combining microchip manufacturing methods and organoid technology and demonstrated the utility of this platform in drug development, disease modelling and precision medicine.
Kasendra’s career spans industry, academia and the start-up world. She performed her PhD project at Novartis Vaccines and Development, which was followed by post-doctoral research fellowship at the Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University. She has authored numerous publications and patents.
High-Throughput Screening (HTS), Imaging, Induced Pluripotent Stem Cells (iPSCs), Informatics, Lab Automation, Screening, Stem Cells, Targets
Dr Magdalena Kasendra, Dr Victoria Marsh Durban